Physician profile
Mohammad A Khalid
NPI 1952303133
$3,621.27
in general payments reported to CMS, 2019-2025
23 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $1,915 · 2021: $133 · 2022: $528 · 2023: $29.23 · 2024: $127 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,547.68 | 2020 | |
| Novartis Pharmaceuticals Corporation | $311.02 | 2019-2025 | |
| Abbott Laboratories | $267.84 | 2022 | |
| Amgen INC. | $199.63 | 2019-2020 | |
| Ekos Corporation | $132.97 | 2019 | |
| Astellas Pharma US INC | $130.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 | |
| Penumbra, INC. | $120.00 | 2022 | |
| Boston Scientific Corporation | $110.22 | 2019-2025 | Ilab Ultrasound Imaging System, Cds - Mct/Cem Monitoring |
| Novo Nordisk INC | $100.65 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $99.87 | 2021 | |
| Pfizer INC. | $98.28 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $92.37 | 2019-2024 | Farxiga |
| Akcea Therapeutics, INC. | $71.88 | 2019 | |
| Biotronik INC. | $45.51 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.91 | 2024 | Jardiance |
| Bard Peripheral Vascular, INC. | $30.19 | 2021-2024 | Lifestream |
| Vifor Pharma, INC. | $27.49 | 2022-2023 | Veltassa |
| E.R. Squibb & Sons, L.L.C. | $16.01 | 2025 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $15.38 | 2024 | |
| Esperion Therapeutics, INC. | $14.96 | 2025 | Nexletol |
| Chiesi USA, INC. | $11.98 | 2019 | |
| Cardinal Health 200 LLC | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.